Genelux (NASDAQ:GNLX) Shares Down 2.7% – Here’s What Happened

27 Feb 2026, 05:52 by Mitch Edgeman · The Markets Daily

Genelux Corporation (NASDAQ:GNLX – Get Free Report) fell 2.7% during mid-day trading on Thursday . The company traded as low as $2.83 and last traded at $2.89. 126,819 shares changed hands during trading, a decline of 30% from the average session volume of 180,775 shares. The stock had previously closed at $2.97.

Analysts Set New Price Targets

A number of research analysts recently commented on GNLX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Genelux in a research report on Monday, January 5th. Finally, Wall Street Zen cut Genelux from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Get Our Latest Stock Analysis on GNLX

Genelux Trading Down 2.7%

The company has a market cap of $109.96 million, a price-to-earnings ratio of -3.28 and a beta of 0.20. The firm has a 50-day moving average price of $3.10 and a 200 day moving average price of $4.23.

Insider Buying and Selling

In other Genelux news, Director John Thomas sold 10,000 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $5.00, for a total transaction of $50,000.00. Following the completion of the sale, the director owned 492,784 shares in the company, valued at $2,463,920. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GNLX. Goldman Sachs Group Inc. acquired a new position in shares of Genelux in the 1st quarter valued at about $239,000. Jane Street Group LLC acquired a new stake in Genelux during the first quarter worth about $190,000. Geode Capital Management LLC lifted its holdings in Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after acquiring an additional 5,596 shares during the last quarter. MAI Capital Management boosted its stake in Genelux by 66,161.3% in the second quarter. MAI Capital Management now owns 236,553 shares of the company’s stock valued at $679,000 after acquiring an additional 236,196 shares during the period. Finally, Private Management Group Inc. acquired a new position in Genelux in the second quarter valued at approximately $33,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

(Get Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.